---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104969"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:55:29.731850+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio Q2 net loss $31.2M; discontinues ADI-270, cuts workforce 30%

## Summary
- Net loss $31.2M ($0.34/sh) vs $29.9M ($0.33/sh) in Q2 2024; R&D spending rose to $28.4M.
- Cash $125.0M as of June 30, 2025, down from $176.3M at year-end 2024; runway into Q4 2026.
- Discontinued ADI-270 for ccRCC; workforce reduced ~30% to extend cash runway.
- Prioritizing ADI-212 (PSMA, prostate cancer); IND filing expected Q1 2026, data 2H 2026.
- Phase 1 ADI-001 autoimmune trial expanded to IIM, SPS, AAV; preliminary data expected 2H 2025.

## SEC filing metadata
- accession: 0000950170-25-104969
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017025104969/0000950170-25-104969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017025104969/acet-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104969
- JSON: https://secwatch.observer/filing/0000950170-25-104969.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.